EQL PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.3 SEK | +0.70% |
|
+1.41% | +29.64% |
| 04-22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
| 02-13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
| Sales 2024 * | 363M 33.19M 2.66B | Sales 2025 * | 425M 38.82M 3.11B | Capitalization | 1.26B 115M 9.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 60M 5.48M 439M | Net income 2025 * | 76M 6.95M 556M | EV / Sales 2024 * | 3.58 x |
| Net Debt 2024 * | 41M 3.75M 300M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.96 x |
| P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
16.5
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.70% | ||
| 1 week | +1.41% | ||
| Current month | +2.36% | ||
| 1 month | +5.61% | ||
| 3 months | +21.97% | ||
| 6 months | +69.80% | ||
| Current year | +29.64% |
1 week
42.40
44.90
1 month
41.7046.00
Current year
33.0046.00
1 year
24.7046.00
3 years
23.0048.70
5 years
9.5048.70
10 years
2.8048.70
| Managers | Title | Age | Since |
|---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 31/01/18 |
| Founder | 59 | 31/12/05 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 14/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 31/12/05 | |
| Director/Board Member | 63 | 31/12/14 | |
| Director/Board Member | 51 | 31/12/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 43.3 | +0.70% | 6,415 |
| 25/04/24 | 43 | -0.92% | 2,142 |
| 24/04/24 | 43.4 | -0.23% | 4,478 |
| 23/04/24 | 43.5 | +2.35% | 12,185 |
| 22/04/24 | 42.5 | -0.47% | 9,771 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Sector
Drug Retailers
Calendar
13/05/2024
- Q4 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.64% | 115M | |
| -32.21% | 15.27B | |
| -31.97% | 10.84B | |
| -30.42% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -0.88% | 4.71B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B |
- Stock Market
- Equities
- EQL Stock
